Task-shifting alcohol interventions for HIV+ persons in Kenya: a cost-benefit analysis by unknown
RESEARCH ARTICLE Open Access
Task-shifting alcohol interventions for HIV+
persons in Kenya: a cost-benefit analysis
Omar Galárraga1, Burke Gao1,2, Benson N. Gakinya3, Debra A. Klein4, Richard G. Wamai5, John E. Sidle6
and Rebecca K. Papas7*
Abstract
Background: Among HIV+ patients, alcohol use is a highly prevalent risk factor for both HIV transmission and poor
adherence to HIV treatment. The large-scale implementation of effective interventions for treating alcohol problems
remains a challenge in low-income countries with generalized HIV epidemics. It is essential to consider an intervention’s
cost-effectiveness in dollars-per-health-outcome, and the long-term economic impact —or “return on investment” in
monetary terms.
Methods: We conducted a cost-benefit analysis, measuring economic return on investment, of a task-shifted cognitive-
behavioral therapy (CBT) intervention delivered by paraprofessionals to reduce alcohol use in a modeled cohort of 13,440
outpatients in Kenya. In our base-case, we estimated the costs and economic benefits from a societal perspective across a
six-year time horizon, with a 3% annual discount rate. Costs included all costs associated with training and administering
task-shifted CBT therapy. Benefits included the economic impact of lowered HIV incidence as well as the improvements
in household and labor-force productivity. We conducted univariate and multivariate probabilistic sensitivity analyses to
test the robustness of our results.
Results: Under the base case, total costs for CBT rollout was $554,000, the value of benefits were $628,000, and the
benefit-to-cost ratio was 1.13. Sensitivity analyses showed that under most assumptions, the benefit-to-cost ratio
remained above unity indicating that the intervention was cost-saving (i.e., had positive return on investment).
The duration of the treatment effect most effected the results in sensitivity analyses.
Conclusions: CBT can be effectively and economically task-shifted to paraprofessionals in Kenya. The intervention
can generate not only reductions in morbidity and mortality, but also economic savings for the health system in
the medium and long term. The findings have implications for other countries with generalized HIV epidemics,
high prevalence of alcohol consumption, and shortages of mental health professionals.
Trial registration: This paper uses data derived from “Cognitive Behavioral Treatment to Reduce Alcohol Use Among
HIV-Infected Kenyans (KHBS)” with ClinicalTrials.gov registration NCT00792519 on 11/17/2008; and preliminary data from
“A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention” (NCT01503255, registered on 12/16/2011).
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Background
Alcohol use is responsible for 13.5% of global deaths due
to infectious diseases including HIV, and 5.1% of
disability-adjusted life years (DALYs) [1, 2]. The high
worldwide alcohol use related morbidity and mortality
suggests an urgent need for a global focus on treatment
of alcohol use disorders [3–5]. Alcohol consumption
negatively impacts the effectiveness of prevention efforts
by facilitating HIV transmission through increased sexual
risk behavior as well as HIV treatment non-adherence
[6–11]. Although dramatic progress against HIV/AIDS
has been made in sub-Saharan Africa [12] –with disease
incidence decreasing by 25% in 22 countries from 1990
to 2009 and treatment access expanding from 50,000 to
over 5 million persons from 2002 to 2012 [13] – the
progress towards “zero new infections and zero AIDS-
related deaths” promoted by UNAIDS [14] is hampered
by several challenges. These include the growing HIV
prevalence due to expanded lifespans, limited accessibility
to antiretrovirals (ARVs), and continued suboptimal
adherence to treatment [13, 14]. While increased ac-
cess to ARVs improves overall health by lowering viral
load and acting as a protective factor [15, 16], the predictive
ability of adherence [17, 18] is strongly mediated by alcohol
use [8, 19–23]. This suggests that alcohol use can present a
significant barrier to the Zero Campaign by increasing HIV
infectivity. The evidence suggests a linear dose-response
relationship between alcohol use and risk for comorbid and
AIDS-defining illnesses [24]. That is, although high levels
of alcohol use are associated with higher rates of AIDS-
related complications and higher health care costs, any
level of alcohol use places a patient at higher risk for
such complications and higher costs—thus suggesting
that there is no “safe” level of alcohol consumption for
HIV-infected patients. For this reason, we consider al-
cohol use of all levels as harmful for HIV+ persons
throughout this paper.
In sub-Saharan Africa, Kenya is among countries with
high and hazardous alcohol consumption, 22.7% of adults
(age 15+) using alcohol within the past 12 months, and an
estimated 3.2% of adults (age 15+) exhibiting alcohol use
disorders [2]. Furthermore in a survey among school-going
Kenyan youth, 48.9% have drunk alcohol [25]. Because
harmful alcohol use behavior is classified as a mental health
disorder, known as alcohol use disorder (or AUD), and
because such behavior can be associated with spread of
HIV [9, 26–28], it is important that those with AUD re-
ceive appropriate mental health treatment. Unfortunately,
throughout much of the world, there exists a large treat-
ment gap between psychiatric service availability and the
high burden of mental disorders including substance
abuse [29]. In Kenya in particular, the Ministry of Health
reports that 20–30% outpatient visits are for mental disor-
ders [30], and only 15% of mental health patients receive
treatment [31]. Furthermore, despite an estimated 25% of
patients in general health clinics suffering from alcohol
and substance abuse disorders, only 0.1% of patients in
general health clinics had their alcohol abuse problems
picked up by clinicians [31]. This is likely because of the
dearth of mental health care workers. In 2010, Kenya
employed approximately 75 psychiatrists, only 12 of
whom work across the eight provincial and 250 district
hospital system – one psychiatrist for every province
of 3–5 million people [32]. There were 250 trained
psychiatric nurses deployed in psychiatry in Kenya, so
approximately one psychiatric nurse per 160,000 Kenyans
[32]. In the current context of acute shortages of specialist
health workers, high alcohol use, and high HIV prevalence
[33–35], there are calls for innovative cost-effective
strategies to reduce alcohol use in sub-Saharan Africa,
and in Kenya in particular [36, 37].
One promising model to accelerate delivery is task-
shifting of services in which tasks performed by profes-
sionals are delegated to those with less formal education
or training called paraprofessionals [38–41]. Shifting
of mental health services through training additional
personnel could be critical to meet demand [32, 42].
Task-shifting to scale-up other HIV prevention interven-
tions in Kenya offers a practical model for healthcare
delivery [43]. Task-shifting HIV and alcohol interventions
may promote behavior change among larger numbers of
people living with HIV, including men who generally
utilize less HIV testing, less therapy and display lower
adherence to care [44–46].
Given the limited number of mental health professionals
in Kenya, we developed a cognitive behavioral therapy
(CBT) to reduce alcohol consumption, and a framework
of paraprofessional training and supervision to task-shift
this CBT. CBT has been shown to positively influence
health behavior by engaging participants in a deliberate
exploration of thoughts, actions and feelings by which par-
ticipants learn coping skills to handle high-risk substance
use situations [47]. CBT was selected for the Kenyan
adaptation because of its strong empirical support in both
individual and group formats to reduce substance abuse
[48, 49], durability of treatment effects, and prior success-
ful applications in sub-Saharan Africa to reduce risky
sexual behaviors among HIV-infected Zambian couples
[50] and to improve mood among Nigerian surgical patients
[51]. Furthermore, because of its highly-structured format,
CBT was feasible for training paraprofessionals and for
delivery to those with limited formal education. On the
contrary, using Medication Assisted Therapy (MAT) was
not feasible in this resource-limited setting due to ex-
tremely limited health care professionals to deliver or monitor
the medication. Additionally, MAT typically requires longer
delivery to curb alcohol use, recommended from 4
months [52] up to 12 months or longer [53].
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In a previous pilot study, we found task-shifted CBT
to be effective at reducing alcohol use, with a reported
alcohol abstinence rate of 69% at a 90 day follow-up (vs.
38% usual care) [47, 54]. As mentioned earlier, all levels
of alcohol use—even low levels—have been shown to
have a negative impact on HIV+ persons [24]. Therefore,
our pilot study included any HIV+ patients who had any
amount of alcohol in the previous month, as well as a
score of 3 on AUDIT-C or endorsement of binge drink-
ing on a monthly basis. Furthermore, the level of compe-
tency of this task-shifted CBT was independently rated
to be equivalent to therapy delivered by college-educated
therapists in the U.S. [47, 54].
The present economic evaluation study has three aims.
First, we describe field-based costs of a feasible rollout
of CBT to reduce alcohol use among 13,440 HIV-infected
outpatients at 12 sites in Kenya. Our assumptions are based
on two CBT trials in western Kenya [47, 54]. Second, we
estimate the potential economic benefits of the rollout
in medium- and long-term based on simulation methods.
Third, we calculate the potential medium to long-term
benefit-to-cost ratio (BCR).
We chose to conduct a cost-benefit analysis for two
reasons. First, previous research suggests that CBT may
be cost-effective in the Kenyan context, but cost-saving
only under very strict assumptions [37]. We hypothe-
sized that including the additional potential economic
impact of the CBT intervention in the Kenyan setting
would provide a more comprehensive assessment. Thus,
cost-benefit analysis (comparing both costs and all benefits
in monetary terms) would be better suited for illustrating
this point than cost-effectiveness analysis (which compares
costs in monetary terms, and effects given only as health
outcomes) or cost-utility analysis (which uses cost per
utility effect such as dollar per quality-adjusted life year)
[55, 56]. To show that CBT is effective and cost-saving is
not a trivial task because only a few interventions are
highly-effective and also save costs [57]. Second, modelling
based on effectiveness outcomes alone has already been
completed using our CBT estimates [36], making cost-
benefit analysis (that includes monetary evaluation of
health and economic benefits) the next logical step in
this line of research. Our cost-benefit analysis offers
useful novel information regarding the health and eco-
nomic benefits of CBT.
Methods
A cost-benefit analysis is an economic evaluation technique
which places a monetary valuation on a health program’s
costs and benefits, allowing for the comparison of a health
program’s incremental cost to its incremental benefits in
corresponding monetary units [58]. The model presented
in this paper estimates the costs and benefits of rolling out
a task-shifted CBT intervention to reduce alcohol use
among persons living with HIV in Kenya from a societal
perspective, including beneficial economic impact over and
above reductions in mortality and morbidity. Benefits in-
cluded those associated with lowered HIV incidence and
improvements in household as well as labor force productiv-
ity (Table 1). Costs included all costs associated with training
and administering task-shifted CBT (Tables 2 and 3). There
is inherent uncertainty when placing a monetary valuation
on a program’s potential future costs and benefits. To
help account for this uncertainty we created sensitivity
analyses which vary our model’s key assumptions across
different ranges as described in the Sensitivity analyses
section of this paper.
Our program implementation model, based on field
operations and expert consultation, contemplates a pro-
gram that services 13,440 participants in 12 sites in
Kenya across five years. In our base case, we assume
the CBT treatment effect is maintained for two years,
meaning that for every year which the intervention is
rolled out, the participants of that year gain benefits
associated with CBT for two years. Thus in our base
case, we assume a 6-year time horizon. The program’s
rollout was constructed from parameters based on our
pilot experience in Eldoret, Kenya among 75 HIV-
infected outpatients who reported hazardous or binge
drinking, and our on-going randomized controlled efficacy
trial with 614 randomized participants. The results, a full
description of the pilot study, and an on-going trial are
described elsewhere [47, 54, 59].
Methods for rollout were based on our previous work,
with some modifications to enhance future sustainability
[47, 54]. For example, while the pilot study was conducted
in a large town (Eldoret) with a tertiary care medical center,
our costs and methods for the rollout are based on deliver-
ing the intervention at the level of district or local hospital
administered by the Ministry of Health. While paraprofes-
sionals in our previous work possessed varying degrees of
formal training from high school diploma to a bachelor’s
degree, salaries and training in the rollout are based on high
school diploma only, to make the intervention more
realistic. Though we condensed the training period
from 4 to 2 weeks in this exercise, we also extended the
paraprofessional counselor consultation up to one year.
Whereas a psychiatrist managed safety concerns (i.e.,
psychiatric risk and alcohol withdrawal symptoms) in
our previous studies, our rollout methods are based on
training diploma nurses to manage safety issues. Finally,
while our past groups were delivered by gender-matched
paraprofessionals, gender of the counselor in same-gender
rollout group may not be always matched. Our rollout
estimates are conservatively based on two counselors at
each of 12 sites delivering two groups per week with eight
same-gender participants per group, amounting to an
annual workload of two counselors at each site would be
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Table 1 Input parameters to model costs and benefits (per CBT participant)
Parameter Value Range Sources/Reference
Benefit 1: Decreased incidence of HIV $41 $39 to $43 See Table 2 and Table 3
Efficacy of alcohol intervention:
Percentage of patients reporting abstinence at 90 day
follow-up (CBT intervention)
69% [54]
Percentage of patients reporting abstinence at 90 day
follow-up (Usual Care)
38% [54]
Difference between intervention and usual care in percentage of
patients reporting abstinence at 90 day follow-up (parameter 1.1)
31% 21% to 41%
Percentage of HIV incidence attributable to alcohol
consumption (parameter 1.2)
13% 1.8 to 16.5% [86]
Consumer Price Index/Inflation Rates:
Average 2009 Kenyan CPI 100 [60]
Average 2010 Kenyan CPI 106.265
Average 2011 Kenyan CPI 121.17
Average 2013 Kenyan CPI 140.103
Costs of treating new case of HIV:
Average non-drug related costs (2009 USD)
Lab tests 32 29.2 to 36.2 [66]
Visits 24 18.8 to 29.2
Support services 0.4 0.10 to 0.90
Fixed costs 32 22.4 to 46.6
Sum of mean non-drug related costs (2013 USD) 124 [66]
Median drug costs in USD:
12 Month tenofovir/3TC/EFV drug regimen (2013 price) 145.47 145.47–280.72 [68]
Benefit 2: Increased Productivity
Labor Force Participation:
Average Monthly Min Wages (parameter 2.4 for LFP hours), USD (KES) 76.93 (6503) 57.42 to 103.60 (4854 to 8757) [87]
Percentage rise in weekly hours worked after ARV treatment
(LFP hours for parameter 2.3)
19% 3.7% to 34% (Normal Distribution,




Increase in female hours spent collecting parameter in past week:
(HP hours for parameter 2.3)
Firewood 1.056 0.15 to 1.96 (Normal distribution,
SE = 0.461)
[78]
Water 1.945 0.86 to 3.03 (Normal distribution,
SE = 0.556)
[78]
Average Hourly Min Wage for House Worker (parameter 2.4 for
HP hours), USD (KES)
0.85 (72) 0.58 to 1.03 (49–87) [87]
Increase in ARV adherence due to increased abstinence:
Hazardous Drinkers (number of patients non-adherent/exposed) 27.54% (19/69) [7]
Non-Drinkers (number of patients non-adherent/exposed) 7.78% (112/1439) [7]
Increase in the likelihood that an HIV+ patient which moves from
non-abstinence to abstinence behavior will be ARV-adherent
(parameter 2.2)
19.75% 14.75% to 24.75% Calculated from above
values
Currency Exchange (1USD: KES) 84.53 [61]
Abbreviations: ARV antiretroviral, CBT cognitive behavioral therapy, CPI consumer price index, KNBS Kenya National Bureau of Statistics, 3TC lamivudine, EFV
efavirenz, GPRM Global Price Reporting Mechanism, KES Kenyan shillings, USD US dollars, SE standard error
Range refers to the min-max interval used for sensitivity analysis
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160 participants per site in year one. In years 2–5, the
counselors are projected to have gained the training and
experience to handle three groups per week, amounting to
320 participants per site. We have added monthly
“maintenance” groups of post-CBT patients who would
like to maintain or sharpen behavioral skills. We have
reduced the rate of transport reimbursement per par-
ticipant because of the rollout to more proximal location
to participants, and we examine a wide range of transport
reimbursement rates in our sensitivity analyses. Program
evaluation methods would be left to each site and could be
accomplished by providing a brief measure of alcohol use
(e.g., AUDIT) before and after intervention participation.
Inflation, exchange rate, discounting, and benefit-to-cost
ratio
Benefits and costs were transformed into constant 2013
USD using the Kenyan consumer price index [60] and
the average Kenyan shillings (KES) to U.S. dollar (USD)
international exchange rate [61]. The value of all future
benefits and costs were discounted at 3% per year. A
benefit-to-cost ratio (BCR) was found by dividing the
total discounted value of the benefits of CBT, by the
total discounted value of the costs of CBT.
Costs
Training costs in the first year included standard salaries
in the communities, per diems for those attending trainings
or traveling for work, and a housing allowance, with rates
set by Kenyan government. Costs per site per year for the
CBT rollout included personnel, furniture, equipment,
supplies and participant transport reimbursement. Based
on available resources at district and local hospitals, we
assumed free provision of a space for the counselors, a
group room, and access to limited psychotropic medi-
cations and benzodiazepines. In our rollout, counselors
would be employed full-time, and diploma nurses part-time
at 25%. For the base case scenario, participant transport
reimbursement was set at 200 KES at each visit.
Total and unit project costs
We estimated the total rollout project costs by adding
the total training costs and the cost per site for 12
sites, discounted future costs (i.e., costs in years 2 to
5), and then divided by the number of projected par-
ticipants across all 12 sites to obtain a per-participant
unit cost.
Benefits
We first measured the value of the economic benefits
for a single outpatient over one year, then discounted
this value over future years and summed the discounted
benefits across all 13,440 CBT participants. This sum
was subsequently employed as the numerator in our
benefit-cost ratio.
Benefit 1: lowered HIV incidence
Alcohol consumption has been shown to increase the
spread of HIV infection [27, 37, 62–65]. A recent study
by Braithwaite et al. showed that alcohol use was respon-
sible for an estimated 13% of new HIV infections; specific-
ally citing our task-shifted pilot model and estimating that
it could prevent nearly half of these new HIV infections
caused by alcohol use [36]. Thus by lowering alcohol con-
sumption, the CBT intervention would avert a large per-
centage of new HIV infections, and could in turn create
future savings in terms of averted medically-related costs.
We modeled the annual savings accrued through averted
costs from reduced likelihood of HIV transmission per
HIV-negative patient as the multiplication product of:
1. The likelihood that a CBT-treated patient will exhibit
abstinence for a year (parameter 1.1)
2. The reduced likelihood that an HIV-negative patient
will be infected given a single HIV+ patient within
the CBT treatment population abstains from alcohol
(parameter 1.2)
3. The cost of treating a case of HIV for a year (from a
provider’s perspective), (parameter 1.3)
The parameter 1.1 was taken from a randomized control
trial done by Papas et al. [54]. This study found that 69% of
CBT participants reported abstinence after a 90 day fol-
low-up, and 38% of the usual care control group reported
abstinence at follow-up. Parameter 1.1 was found by sub-
tracting the difference between the treatment group and
the control group. The parameter 1.2 was found from a
simulation model of HIV disease progression and transmis-
sion by Braithwaite et al. [36]. Through a 135-article review,
Braithwaite et al. identified and modeled three conse-
quences of alcohol-use which increase the incidence of
HIV transmission: increased risk of condom non-use, in-
creased risk of ARV non-adherence, and increased STI
prevalence. Braithwaite et al.’s model estimated 13% of new
HIV infections in Kenya were attributable to alcohol use.
Parameter 1.3 was found by summing the costs of anti-
retroviral drugs (ARVs), clinic visits, lab tests, clinic support
services, and hospital fixed costs (costs related to cleaners,
hospital equipment, etc.). All costs except the cost of ARVs
were taken from a cross-sectional survey by Larson et al.,
which looked at patient level cost data across three different
clinics in Kenya [66]. The World Health Organization
(WHO) recommends tenofovir/3TC/EFV as a first-line
ARV treatment [67], and the annual cost of tenofovir/
3TC/EFV in Kenya was found using the WHO’s Global
Price Reporting Mechanism [68].
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Benefit 2: increased labor force and household
productivity
Studies have shown that alcohol consumption is posi-
tively correlated with ARV non-adherence; and con-
versely, that lower levels of alcohol consumption and
abstinence are associated with better ARV adherence
[7, 69, 70]. CBT—in reducing alcohol consumption—-
has been identified as a method to increased ARV
adherence [71–73]. ARV adherence and its resulting
medical and functional benefits, in turn, have been shown
to increase labor force participation (LFP) [74–77] and in-
crease household productivity (HP) [78]. Thus, through a
mechanism of ARV adherence, CBT can increase LFP and
HP. We estimated the monetary benefits of LFP and HP
as per person-year values. These monetary benefits were
calculated as the multiplicative product of:
1. The likelihood that a CBT-treated patient will exhibit
abstinence for a year (same value as in benefit 1, i.e.
parameter 1.1). Note that we do not call this parameter
2.1, but parameter 1.1. We also do not name any
variables in this paper as parameter 2.1 in order to
avoid confusion.
2. The increase in the likelihood that an HIV+ patient
who moves from non-abstinence to abstinence behavior
will be ARV-adherent. (Parameter 2.2)
3. The additional ARV-related hours worked annually
per person from increased LFP/HP (the additional
hours for LFP were used to calculate the value of
the benefits for LFP, and the additional hours for HP
were used calculate the value of the benefits for HP).
(Parameter 2.3)
4. The corresponding wage value for the hours
measured in parameter 2.3. (Parameter 2.4)
A major challenge in estimating parameters 2.2 and 2.3
was accounting for potential patient differences in ARV-
adherence and ARV-initiation respectively. In estimating
parameter 2.3, in order to take into account different levels
of ARV-adherence, multiple levels of ARV-adherence
would need to measured and tracked within a Kenyan
population. Such data was not available. Patient differ-
ences in ARV-treatment initiation times, meanwhile, can
potentially bias measurements of parameter 2.3. Those
who initiated ARV-treatment before CBT-treatment are
likely to exhibit lower positive benefits from increases in
ARV-adherence than those who initiated ARVs during
CBT-treatment (and would move from no ARV-treatment
to full ARV-adherence post-CBT treatment).
We address problems associated with different levels
in ARV-adherence in our estimation of parameter 2.2 by
looking only at the effect of full ARV-adherence, and
categorizing all other levels of adherence as non-
adherence. This binary indicator implies that we need
only find the effect of abstinence on increasing the likeli-
hood that a patient moves from any given level of ARV-
adherence below full adherence (i.e. non-adherence) to
full adherence, rather than tracking multiple movements
across multiple levels of ARV-adherence. Thus param-
eter 2.2 was found from a cross-sectional survey of 2920
ARV-treated patients from clinics in Cote d’Ivoire,
Benin, and Mali by Jaquet et al. [7]. To estimate param-
eter 2.2, we subtracted the fraction of non-drinkers
which were non-adherent from the fraction of hazardous
drinkers which were non-adherent.
To deal with potential ARV-initiation-related bias in the
estimation of Parameter 2.3, we used results from the indi-
vidual fixed-effects regressions of studies which measured
the effects of ARV-adherence on random samples of
Kenyan patients [74, 78]. By measuring the effect of ARV-
adherence on productivity in a random sample of patients,
the ARV-initiation times of the studied population likely
resemble our modeled CBT treatment population, and thus
the measured effect used in our input of Parameter 2.3
already takes into account the differences in ARV-initiation
of our modeled population. We use results from a study by
Thirumurthy et al. to measure the LFP hours of parameter
2.3, using coefficients from their regression of LFP on con-
sistent 6-month ARV-adherence [74]. The value of the per
person-year values of the gains in LFP was counted for
both men and women, because the regression coefficients
were found using control groups comprised of patients
from randomly selected households from Kenyan census
data and the treatment groups comprised of patients from
randomly selected households from the Mosoriot health
clinic in Kenya. This random selection ensures that
although men are more likely to be engaged in labor market
activities than women [74], the results take this into account
and can be applied across men and women.
The value of the per person-year values of the gains in
HP, on the other hand, was counted only for women, as
the regression coefficients from which the HP hours of
parameter 2.3 was estimated were specific to female
household productivity [78]. We assumed that half of
our simulated population was female.
The LFP value for parameter 2.4 was found by taking
the mean across all monthly minimum wage listings
from the Kenyan Ministry of Labor’s 2013 Regulation of
Wages, and multiplying this number by 12 to yield an
annual estimate. Similarly, the HP value for parameter
2.4 was found by taking the mean hourly wage for a
house worker across all geographic locations.
Statistical and sensitivity analyses
To characterize and take into account the potential error
of the studies used for the parameters of our base case,
we first conducted one-way sensitivity analyses where
we changed all inputs, one at a time, across a range of
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values. The value of the bounds of this range was found
by taking the 95% confidence interval (CI) around the
base case values; or if the CI was unavailable, the abso-
lute range of values for which the input was observed. In
the cases of the cost of CBT rollout per participant, par-
ameter 1.1 and parameter 2.2, literature values for
ranges were not available, so we chose a broad range of
values around the base case to reasonably test robust-
ness. In addition to the inputs listed in Table 1, we also
varied the treatment effect length, the discount rate, and
participant transport reimbursement.
Additionally, to further characterize the inherent uncer-
tainty all inputs in Table 1 were simultaneously varied in a
Monte Carlo simulation where, for each cohort of partici-
pants, data was drawn from the same ranges as in the one-
way sensitivity analysis. Simulations assumed a logarithmic
(right-skewed) distribution for costs, a normal distribution
for inputs whose ranges were CIs (with a standard deviation
equal to the standard error used to calculate the CI), and
uniform distribution for all other ranges. We ran Monte
Carlo simulations with 10,000 replications for each inde-
pendent cohort of 13,440 participants using multiprocessor
Stata 14 [79]. All simulations assumed the base case 3%
discount rate, and the treatment effect length was set to
either one, two, three, four, five, or ten years for each set of
10,000 replications. All sets of replications for each treat-
ment effect length are listed in Fig. 3. For both univariate
and probabilistic sensitivity analyses, when the treatment
effect length was adjusted, the time horizon was also
adjusted as well to take into account the final group’s bene-
fits across the treatment effect length.
Results
The overall benefit-cost ratio was 1.13. Figure 1 summa-
rizes the costs and benefits for the base case CBT imple-
mentation (costs are in the first bar labeled in gray, benefits
are shown in the second bar labeled in blue). Training costs
in the first year were $158,000, which were higher than sub-
sequent years, primarily due to personnel costs. However,
costs declined across the final four years to about $94,000
in year 5. The total discounted cost over the five-year roll-
out was approximately $554,000. Over the five year period,
the average cost-per-participant was $44. (Cost breakdowns
are presented in Tables 2 and 3). Benefits totaled $49,000;
$118,000; $137,000; $133,000; $129,000; and $62,000 in
years 1, 2, 3, 4, 5, and 6 respectively. Note that benefits
continued in year 6, despite the costs of the program end-
ing in year 5. The average annual savings from decreased
HIV incidence (benefit 1) was $11 per patient; and the
annual value for increased productivity (benefit 2) was
$14.50 per patient. The total value of benefit 1 and
benefit 2 was estimated to be approximately $628,000.
Figure 2 shows the input variables that most affected
the base case scenario in one-way sensitivity analyses.
For nearly all inputs shown in Fig. 2, CBT remained
cost-savings with a benefit-cost ratio greater than 1. Not
pictured in Fig. 2 are values associated with non-drug
related inputs associated with parameter 1.3. These four
inputs had little effect on the benefit-cost ratio, and when
varied across their ranges, yielded benefit-cost ratio ranges
of: 1.138 to 1.140 (support services); 1.13 to 1.15 (lab
tests); 1.13 to 1.15 (visits); and 1.11 to 1.18 (fixed costs).
Also not shown in Fig. 2 is the uncertainty associated with
the assumed treatment effect length. When we adjusted
our assumption to the treatment effect lasting 1, 5 and 10
years, the benefit-cost ratio changed to 0.58; 2.72; and
5.05 respectively.
In Fig. 3, we further characterize the inherent uncer-
tainty in the parameters by summarizing the probabilistic
sensitivity analyses. The results were split into groups
based on treatment effect duration; for each group we
present separate Monte Carlo simulations with 10,000
Fig. 1 Costs and potential benefits accrued (in time-discounted 2013 USD). Figure 1 illustrates the monetary costs and potential benefits from a
cognitive behavioral therapy which would be used to reduce alcohol abuse among 13,440 persons living with HIV in Kenya. Values of cost and
benefits were discounted at a rate of 3% assuming that they occur at the end of each year, thus costs in year 1 were not discounted
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repetitions, each with an independent sample of 13,440
participants. The mean benefit-cost ratio under assump-
tions that the CBT treatment effect lasted for 1, 2, 3, 4, 5
or 10 years was 0.65 (95% CI 0.64–0.66); 1.28 (95% CI:
1.26–1.31); 1.90 (95% CI 1.86–1.94); 2.49 (95% CI 2.44–
2.55); 3.07 (95% CI 3.01–3.14); and 5.72 (95% CI: 5.61–
5.84) respectively.
Discussion
Previous research—which used only health outcomes—
showed that CBT was generally cost-effective, but only
cost-saving under strict assumptions (i.e., program costs
of less than $1 per individual) [36, 37]. In this study,
across a broad range of assumptions, task-shifted CBT
was not only favorable, but even cost-saving from a societal
perspective, when we included health and economic
productivity benefits. Our base-case scenario showed a
benefit-cost ratio of 1.13 when the treatment effects
were assumed to last two years; and the benefit-cost ratio
increased to 1.90 with a 3-year treatment maintenance
scenario.
Our results are consistent with a related exercise
which characterized task-shifted CBT for alcohol use
reduction in Kenya as cost-effective [37]. However, the
extant results go further, showing not only reductions in
morbidity and mortality associated with the scale-up,
but also monetary cost-savings for the system as a whole
in Kenya. Some costs included in our analyses such as
specific per-diem rates and housing allowances, are set
by the Kenyan government. These are likely not required
in other sub-Saharan African countries, so the benefit-
cost ratio would likely be higher in those settings. The
Fig. 2 One-way sensitivity analyses for input variables that most affect the base case results. In the figure above, “Rise in labor force participation”
is a measure of the percentage rise in weekly hours worked after ARV treatment; “Alcohol-attributable HIV incidence” is the percentage of HIV
incidence attributable to alcohol consumption; “Rise in ARV-adherence” is the Increase in the likelihood that an HIV+ patient which moves from
non-abstinence to abstinence behavior will be ARV-adherent; “Rise in abstinence due to CBT” is the Difference between intervention and usual
care in percentage of patients reporting abstinence at 90 day follow-up; “Monthly Min Wage” is a measure of the Average Monthly Minimum
Wage in Kenya in USD; “12 Month tenofovir/3TC/EFV” is the cost of a 12 Month tenofovir/3TC/EFV drug regimen expressed in 2013 USD; “Rise in
hours collecting water” is the increase in female hours spent collecting water in past week; “Costs of CBT” is the cost of the CBT rollout per participant; “Rise
in hours spent collecting firewood” is the increase in female hours spent collecting firewood in past week; “House worker min wage” is the Average Hourly
Minimum Wage for House Worker. The numbers in the parentheses represent the upper and lower bounds of the sensitivity analysis. The numbers listed
at the left and right hand side of the bars represent the benefit to cost ratio which would result from the target variable taking on the corresponding max
or min value. Note that the vertical axis is at 1.13, but that all cost-benefit ratios above 1.0 are cost-saving and thus most variables maintain that CBT is cost
saving across the entire range of variables. Ratios rounded to nearest hundredth. Abbreviations: BCR, benefit-to-cost ratio; CBT, cognitive behavioral therapy.
The vertical axis intersects the horizontal axis at approximately 1.13
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provision of transport reimbursement increases the cost
of the intervention, but likely enhances the effectiveness
of the intervention by facilitating better attendance.
A strength of this study is that the scale-up was con-
structed using in-depth knowledge and data of the
training and implementation of CBT procedures from
two clinical trials. The costing exercise presents a novel
and realistic way of shifting the CBT tasks to paraprofes-
sionals in an organized, feasible and scalable manner.
The training, enrollment and compensation procedures
Fig. 3 Distribution of benefit-to-cost ratios from Monte Carlo simulations. Figure 3 shows the results of our probabilistic sensitivity analysis with
discounted net benefits. Separate sets of simulations were independently run for the assumption that program effect duration was 1, 2, 4, 5, or
10 years. Each set of simulations was made up of 10000 repetitions done across an independent sample of 13440 participants. Each set of simula-
tions is also shown with a separate graph
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have been implemented in our past and current trials.
Furthermore, the potential economic benefits are based
on rigorous analyses based in Kenya with the same or
similar populations [74, 78], and have been recognized
to be more widely applicable [80]. The effect of this
approach could support the country’s 2010 Alcoholic
Drinks Control Act which seeks to tighten legislation
against alcohol abuse while also, for the first time, ensur-
ing the right to access to treatment programs [81].
The input parameter most affecting the results was the
duration of CBT-alcohol reduction treatment effects. It
was difficult to choose a base case scenario because evi-
dence regarding the long-term effect length of CBT for
alcohol-use reduction is limited. One reason may be
because the length of follow-up of CBT studies is often
constrained by the time limits of grant cycles. Despite
these limitations, there is reason to believe that CBT
treatment effects could be maintained over a long period
without major reductions in effectiveness. In a 128-person
treatment sample, Kadden and colleagues observed only
marginal reductions in treatment effects in alcohol use at
18-month post-treatment follow up; including a group
CBT condition [82, 83]. Although we felt a base case of a
two-year effect was reasonable, given the uncertainty
surrounding the treatment effects, we also conducted
sensitivity analyses where the base case treatment effect
was adjusted to 1, 5, and 10 years. Our sensitivity analysis
showed that our base case results held for treatment effect
lengths greater than two years, but at a one-year duration
assumption, CBT did not achieve cost-neutrality. This
exercise in modeling reveals that while a task-shifted CBT
has excellent potential for considerable cost-savings, if
treatment effects are particularly short, it is unlikely that
CBT will be cost-savings. It may still be highly cost-
effective (i.e., averting a DALY for less than the per capita
GDP), but it may not save money to the government in
the long run. Again, very few interventions achieve the
status of cost saving [84, 85].
This study has limitations. First, the CBT effects are
based on a small pilot study. Thus, we are currently con-
ducting a larger trial, and expect to update the results
presented here in future research. Second, due to the
limited information regarding the effects of various levels of
adherence, we have dichotomized the treatment effect of
our modeled CBT as “abstinent” vs. “non-abstinent. It is
possible that if continuous data were available regarding the
effect of reducing drinking by one drink, then our modeled
CBT would be shown to have even greater levels of benefits
in terms of ARV adherence and reduced HIV infectivity
given the positively correlation between alcohol use and
these modeled benefits [7, 31, 36, 37, 64–67, 71–73]. Third,
cost-benefit models regarding future cost-savings carry
inherent uncertainty as assumptions must be made re-
garding the consequences of an intervention. As discussed
above, the input parameter most affecting CBT treatment
cost-neutrality was the CBT treatment effect maintenance.
However, to deal with the uncertainty of this and all other
variables, we conducted various sensitivity analyses:
assumptions regarding the parameters in this model were
varied one at a time, as well as simultaneously across
ranges presented in the literature.
Conclusion
A scaled-up task-shifted CBT intervention to reduce
alcohol use among HIV+ persons receiving ARVs can be
not only cost-effective but also potentially cost-saving in
settings such as Kenya, with generalized HIV epidemics
and high rates of alcohol use. This analysis can be helpful
for other countries planning to use task-shifting of CBT to
reduce alcohol use, not only to reduce morbidity and mor-
tality related to HIV disease, but also to generate potential
economic gains. In particular, the study demonstrates how
ex ante economic evaluation results may be generated such
that countries can evaluate the effectiveness of other mental
and public health approaches to improving ARV adher-
ence, reducing risk sexual behaviors, and reducing HIV
incidence.
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